[go: up one dir, main page]

WO2008081701A1 - Ｈｌａ－ａ＊１１０１拘束性ｗｔ１ペプチド、およびそれを含む医薬組成物 - Google Patents

Ｈｌａ－ａ＊１１０１拘束性ｗｔ１ペプチド、およびそれを含む医薬組成物 Download PDF

Info

Publication number
WO2008081701A1
WO2008081701A1 PCT/JP2007/074146 JP2007074146W WO2008081701A1 WO 2008081701 A1 WO2008081701 A1 WO 2008081701A1 JP 2007074146 W JP2007074146 W JP 2007074146W WO 2008081701 A1 WO2008081701 A1 WO 2008081701A1
Authority
WO
WIPO (PCT)
Prior art keywords
peptide
hla
amino acid
restricted
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2007/074146
Other languages
English (en)
French (fr)
Inventor
Haruo Sugiyama
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
International Institute of Cancer Immunology Inc
Original Assignee
International Institute of Cancer Immunology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CN2007800487491A priority Critical patent/CN101573448B/zh
Priority to BRPI0720988-6A priority patent/BRPI0720988A2/pt
Priority to JP2008552080A priority patent/JP5484734B2/ja
Priority to CA002670658A priority patent/CA2670658A1/en
Priority to MX2009007008A priority patent/MX2009007008A/es
Priority to EP15181734.3A priority patent/EP2980219B1/en
Priority to KR1020097013472A priority patent/KR101525261B1/ko
Priority to EP07850650A priority patent/EP2098595A4/en
Priority to UAA200907944A priority patent/UA103154C2/uk
Priority to AU2007340679A priority patent/AU2007340679B2/en
Priority to US12/521,533 priority patent/US8653038B2/en
Priority to RU2009128979/10A priority patent/RU2481398C2/ru
Priority to NZ577443A priority patent/NZ577443A/en
Application filed by International Institute of Cancer Immunology Inc filed Critical International Institute of Cancer Immunology Inc
Publication of WO2008081701A1 publication Critical patent/WO2008081701A1/ja
Priority to ZA2009/03633A priority patent/ZA200903633B/en
Priority to IL199052A priority patent/IL199052A0/en
Anticipated expiration legal-status Critical
Priority to NO20092774A priority patent/NO20092774L/no
Priority to IL215333A priority patent/IL215333A0/en
Priority to IL215332A priority patent/IL215332A0/en
Priority to IL215334A priority patent/IL215334A0/en
Priority to US14/140,698 priority patent/US9272026B2/en
Priority to PH12014500902A priority patent/PH12014500902B1/en
Priority to US15/003,882 priority patent/US20160199472A1/en
Priority to US15/796,368 priority patent/US20180064795A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001152—Transcription factors, e.g. SOX or c-MYC
    • A61K39/001153—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4242—Transcription factors, e.g. SOX or c-MYC
    • A61K40/4243—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)

Abstract

　本発明は、ＨＬＡ－Ａ＊１１０１拘束性ＷＴ１ペプチド、詳細には、ＷＴ１タンパク質由来の９個の連続するアミノ酸からなるアミノ酸配列を含むペプチドであって、ＨＬＡ－Ａ＊１１０１分子と結合能を有し、かつＣＴＬ誘導能を有するペプチド、および少なくとも１個のシステイン残基を含むＷＴ１タンパク質由来の９個の連続するアミノ酸からなるアミノ酸配列を含む２個のペプチド単量体が、ジスルフィド結合により互いに結合しているペプチド二量体であって、ＨＬＡ－Ａ＊１１０１分子と結合能を有し、かつＣＴＬ誘導能を有する、ペプチド二量体に関する。さらに本発明は、該ペプチドをコードするポリヌクレオチド、それらを含む癌治療および／または予防用医薬組成物などに関するものである。
PCT/JP2007/074146 2006-12-28 2007-12-14 Ｈｌａ－ａ＊１１０１拘束性ｗｔ１ペプチド、およびそれを含む医薬組成物 Ceased WO2008081701A1 (ja)

Priority Applications (23)

Application Number Priority Date Filing Date Title
NZ577443A NZ577443A (en) 2006-12-28 2007-12-14 Hla-a*1101-restricted wt1 peptide and pharmaceutical composition comprising the same
JP2008552080A JP5484734B2 (ja) 2006-12-28 2007-12-14 Ｈｌａ−ａ＊１１０１拘束性ｗｔ１ペプチド、およびそれを含む医薬組成物
CA002670658A CA2670658A1 (en) 2006-12-28 2007-12-14 Hla-a*1101-restricted wt1 peptide and pharmaceutical composition comprising the same
MX2009007008A MX2009007008A (es) 2006-12-28 2007-12-14 Peptido wt1 restringido a hla-a*1101 y composicion farmaceutica que comprende el mismo.
EP15181734.3A EP2980219B1 (en) 2006-12-28 2007-12-14 Hla-a*1101-restricted wt1 peptide and pharmaceutical composition comprising the same
KR1020097013472A KR101525261B1 (ko) 2006-12-28 2007-12-14 Ｈｌａ-ａ*1101 구속성 ｗｔ1 펩티드 및 이를 포함하는 의약 조성물
BRPI0720988-6A BRPI0720988A2 (pt) 2006-12-28 2007-12-14 Peptídeo wt1 hla-a*1101 restrito e composição farmacêutica compreendendo o mesmo
UAA200907944A UA103154C2 (uk) 2006-12-28 2007-12-14 Hla-a*1101-обмежений пептид wt1 і фармацевтична композиція, яка містить його
AU2007340679A AU2007340679B2 (en) 2006-12-28 2007-12-14 HLA-A*1101-restricted WT1 peptide and pharmaceutical composition comprising the same
US12/521,533 US8653038B2 (en) 2006-12-28 2007-12-14 HLA-A* 1101-restricted WT1 peptide and pharmaceutical composition comprising the same
EP07850650A EP2098595A4 (en) 2006-12-28 2007-12-14 HLA-A * 1101 RESTRICTED WT1 PEPTIDE AND PHARMACEUTICAL COMPOSITION CONTAINING THEREOF
CN2007800487491A CN101573448B (zh) 2006-12-28 2007-12-14 Hla-a*1101限制的wt1肽及含有其的药物组合物
RU2009128979/10A RU2481398C2 (ru) 2006-12-28 2007-12-14 Hla-a*1101-ограниченный пептид wt1 и содержащая его фармацевтическая композиция
ZA2009/03633A ZA200903633B (en) 2006-12-28 2009-05-26 Hla-a*1101-restricted wt1 peptide and pharmaceutical composition comprising the same
IL199052A IL199052A0 (en) 2006-12-28 2009-06-01 Hla-a*1101-restricted wt1 peptide and pharmaceutical composition comprising the same
NO20092774A NO20092774L (no) 2006-12-28 2009-07-27 HLA-A*1101-begrenset WT1-peptid og farmasoytisk preparat som omfatter dette
IL215333A IL215333A0 (en) 2006-12-28 2011-09-22 Hla-a*1101-restricted wt1 peptide and pharmaceutical composition comprising the same
IL215332A IL215332A0 (en) 2006-12-28 2011-09-22 Hla-a*1101-restricted wt1 peptide and pharmaceutical composition comprising the same
IL215334A IL215334A0 (en) 2006-12-28 2011-09-22 Hla-a*1101-restricted wt1 peptide and pharmaceutical composition comprising the same
US14/140,698 US9272026B2 (en) 2006-12-28 2013-12-26 HLA-A*1101-restricted WT1 peptide and pharmaceutical composition comprising the same
PH12014500902A PH12014500902B1 (en) 2006-12-28 2014-04-24 Hla-a* 1101-restricted wt1 peptide and pharmaceutical composition comprising the same
US15/003,882 US20160199472A1 (en) 2006-12-28 2016-01-22 Hla-a* 1101-restricted wt1 peptide and pharmaceutical composition comprising the same
US15/796,368 US20180064795A1 (en) 2006-12-28 2017-10-27 Hla-a* 1101-restricted wt1 peptide and pharmaceutical composition comprising the same

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006355356 2006-12-28
JP2006-355356 2006-12-28

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/521,533 A-371-Of-International US8653038B2 (en) 2006-12-28 2007-12-14 HLA-A* 1101-restricted WT1 peptide and pharmaceutical composition comprising the same
US14/140,698 Division US9272026B2 (en) 2006-12-28 2013-12-26 HLA-A*1101-restricted WT1 peptide and pharmaceutical composition comprising the same

Publications (1)

Publication Number Publication Date
WO2008081701A1 true WO2008081701A1 (ja) 2008-07-10

Family

ID=39588385

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2007/074146 Ceased WO2008081701A1 (ja) 2006-12-28 2007-12-14 Ｈｌａ－ａ＊１１０１拘束性ｗｔ１ペプチド、およびそれを含む医薬組成物

Country Status (27)

Country Link
US (4) US8653038B2 (ja)
EP (6) EP2098595A4 (ja)
JP (1) JP5484734B2 (ja)
KR (1) KR101525261B1 (ja)
CN (5) CN101573448B (ja)
AR (1) AR064555A1 (ja)
AU (1) AU2007340679B2 (ja)
BR (1) BRPI0720988A2 (ja)
CA (5) CA2886621A1 (ja)
CY (1) CY1116011T1 (ja)
DK (3) DK2479275T3 (ja)
ES (4) ES2526425T3 (ja)
IL (4) IL199052A0 (ja)
MX (1) MX2009007008A (ja)
MY (1) MY161664A (ja)
NO (1) NO20092774L (ja)
NZ (4) NZ592509A (ja)
PH (1) PH12014500902B1 (ja)
PL (1) PL2341142T3 (ja)
PT (1) PT2341142E (ja)
RU (1) RU2481398C2 (ja)
SG (1) SG177222A1 (ja)
SI (1) SI2341142T1 (ja)
TW (3) TWI417103B (ja)
UA (1) UA103154C2 (ja)
WO (1) WO2008081701A1 (ja)
ZA (1) ZA200903633B (ja)

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014098012A1 (ja) * 2012-12-17 2014-06-26 大塚製薬株式会社 ヘルパーt細胞の活性化方法
EP2762160A1 (en) 2013-02-05 2014-08-06 Nitto Denko Corporation Wt1 peptide cancer vaccine composition for mucosal administration
EP2762159A1 (en) 2013-02-05 2014-08-06 Nitto Denko Corporation WT1 peptide cancer vaccine composition for transdermal administration
EP2762155A2 (en) 2013-02-05 2014-08-06 Nitto Denko Corporation Vaccine Composition
EP2762154A2 (en) 2013-02-05 2014-08-06 Nitto Denko Corporation Vaccine composition for transdermal administration
EP2762157A1 (en) 2013-02-05 2014-08-06 Nitto Denko Corporation Vaccine composition for transdermal or mucosal administration
EP2762153A2 (en) 2013-02-05 2014-08-06 Nitto Denko Corporation Vaccine composition for mucosal administration
EP2762152A1 (en) 2013-02-05 2014-08-06 Nitto Denko Corporation WT1 peptide cancer vaccine composition for transdermal administration
EP2762156A1 (en) 2013-02-05 2014-08-06 Nitto Denko Corporation Tape preparation of WT1 peptide cancer vaccine for transdermal administration
WO2014157692A1 (ja) * 2013-03-29 2014-10-02 大日本住友製薬株式会社 Ｗｔ１抗原ペプチドコンジュゲートワクチン
WO2014157704A1 (ja) * 2013-03-29 2014-10-02 大日本住友製薬株式会社 Ｅｒａｐ１によるトリミング機能をきっかけとしたコンジュゲートワクチン
US20160009781A1 (en) 2012-09-12 2016-01-14 International Institute Of Cancer Immunology, Inc. Antigen-specific helper t-cell receptor genes
WO2016093326A1 (ja) * 2014-12-11 2016-06-16 株式会社癌免疫研究所 血管新生病の免疫療法
US10124046B2 (en) 2003-11-05 2018-11-13 International Institute Of Cancer Immunology, Inc. HLA-DR-binding antigen peptide derived from WT1
US10139395B2 (en) 2007-02-27 2018-11-27 International Institute Of Cancer Immunology, Inc. Method for activation of helper T cell and composition for use in the method
WO2019131722A1 (ja) * 2017-12-27 2019-07-04 大日本住友製薬株式会社 Ｗｔ１由来ペプチドのコンジュゲート体およびこれを含む組成物
US10654892B2 (en) 2010-10-05 2020-05-19 International Institute Of Cancer Immunology, Inc. Method for activating helper T cell
WO2021230247A1 (ja) * 2020-05-12 2021-11-18 大日本住友製薬株式会社 癌を処置するための医薬組成物
US12383608B2 (en) 2016-11-30 2025-08-12 Sumitomo Pharma Co., Ltd. WT1 helper peptides and combinations of WT1 helper peptide and conjugate of cancer antigen peptides

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2565201B1 (en) 2005-10-17 2014-11-26 Sloan-Kettering Institute For Cancer Research WT1 HLA class II-binding peptides and compositions and methods comprising same
EP3117836A1 (en) 2006-04-10 2017-01-18 Sloan Kettering Institute For Cancer Research Immunogenic wt-1 peptides and uses thereof
JP6082997B2 (ja) * 2011-04-01 2017-02-22 メモリアル スローン−ケタリング キャンサー センター Ｈｌａ−ａ２により提示されるｗｔ１ペプチドへのｔ細胞受容体様抗体
EP2757373A4 (en) 2011-09-14 2015-07-01 Int Inst Cancer Immunology Inc METHOD FOR MEASURING ANTI-WT1 ANTIBODIES
AU2013207669C1 (en) 2012-01-13 2018-05-31 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
CN105121715B (zh) 2012-12-11 2018-10-26 艾伯特叶史瓦大学爱因斯坦医学院 高通量受体:配体鉴定方法
PT2945647T (pt) 2013-01-15 2020-11-26 Memorial Sloan Kettering Cancer Center Péptidos imunogénicos wt-1 e métodos de uso dos mesmos
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
CA3022331A1 (en) 2016-05-18 2017-11-23 Albert Einstein College Of Medicine, Inc. Variant pd-l1 polypeptides, t-cell modulatory multimeric polypeptides, and methods of use thereof
CN109475628A (zh) 2016-05-18 2019-03-15 库尔生物制药有限公司 T细胞调节性多聚体多肽及其使用方法
AU2017379900B2 (en) 2016-12-22 2024-12-05 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
WO2018129474A1 (en) 2017-01-09 2018-07-12 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
EP3596118B1 (en) 2017-03-15 2024-08-21 Cue Biopharma, Inc. Combination of multimeric fusion polypeptides and immune checkpoint inhibitor for treating hpv-associated cancer
WO2019139896A1 (en) 2018-01-09 2019-07-18 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
DE112019001654B4 (de) 2018-03-29 2024-10-17 Rohm Co., Ltd. Halbleiterbauteil
EP4149534A4 (en) 2020-05-12 2024-09-04 Cue Biopharma, Inc. MULTIMERIC POLYPEPTIDES MODULATING T CELLS AND METHODS OF USE THEREOF
WO2022056014A1 (en) 2020-09-09 2022-03-17 Cue Biopharma, Inc. Mhc class ii t-cell modulatory multimeric polypeptides for treating type 1 diabetes mellitus (t1d) and methods of use thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002028414A1 (en) 2000-10-06 2002-04-11 Corixa Corporation Compositions and methods for wt1 specific immunotherapy
JP2003524021A (ja) * 2000-02-22 2003-08-12 コリクサ コーポレイション 悪性中皮腫の診断および治療のための組成物および方法
WO2003106682A1 (ja) 2002-06-12 2003-12-24 中外製薬株式会社 Ｈｌａ−ａ２４拘束性癌抗原ペプチド
JP2005518192A (ja) * 2001-10-30 2005-06-23 コリクサ コーポレイション Ｗｔ１特異的免疫療法のための組成物および方法
WO2005095598A1 (ja) 2004-03-31 2005-10-13 International Institute Of Cancer Immunology, Inc. Ｗｔ１由来の癌抗原ペプチド
JP2006045287A (ja) 2004-08-02 2006-02-16 Inax Corp 弾性接着剤及びタイル張り壁面
JP2006280324A (ja) * 2005-04-04 2006-10-19 Ehime Univ Ｈｌａクラスｉｉ拘束性ｗｔ１抗原ペプチド

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4575374A (en) * 1983-02-16 1986-03-11 Anis Aziz Y Flexible anterior chamber lens
US5763209A (en) * 1988-09-26 1998-06-09 Arch Development Corporation Methods and materials relating to the functional domains of DNA binding proteins
US5584304A (en) * 1993-11-18 1996-12-17 Allergan, Inc. Method of inserting an IOL using a forceps inside a folding tube
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US5984962A (en) * 1996-01-22 1999-11-16 Quantum Vision, Inc. Adjustable intraocular lens
US6207375B1 (en) * 1996-12-11 2001-03-27 Mayo Foundation For Medical Educational & Research TGF-β inducible early factor-1 (TIEF-1) and a method to detect breast cancer
BR9914116A (pt) * 1998-09-30 2002-01-15 Corixa Corp Composições e métodos para imunoterapia especìfica de wt1
US7063854B1 (en) * 1998-09-30 2006-06-20 Corixa Corporation Composition and methods for WTI specific immunotherapy
US7144581B2 (en) * 2000-10-09 2006-12-05 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US20030039635A1 (en) 1998-09-30 2003-02-27 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7115272B1 (en) 1998-09-30 2006-10-03 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7655249B2 (en) * 1998-09-30 2010-02-02 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7901693B2 (en) 1998-09-30 2011-03-08 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
BR0009505A (pt) * 1999-04-02 2002-06-11 Corixa Corp Compostos e processos para terapia e diagnóstico de câncer de pulmão
AU7859900A (en) * 1999-10-04 2001-05-10 Corixa Corporation Compositions and methods for wt1 specific immunotherapy
US20030082194A1 (en) 2000-02-22 2003-05-01 Alexander Gaiger Compositions and methods for diagnosis and therapy of malignant mesothelioma
US20040097703A1 (en) * 2001-03-22 2004-05-20 Haruo Sugiyama Wt1 modified peptide
IL145015A0 (en) * 2001-08-21 2002-06-30 Nun Yehoshua Ben Accommodating lens
US7553494B2 (en) * 2001-08-24 2009-06-30 Corixa Corporation WT1 fusion proteins
JP4377323B2 (ja) 2002-06-14 2009-12-02 メルク エンド カムパニー インコーポレーテッド 有糸分裂キネシン阻害剤
SE0201863D0 (en) * 2002-06-18 2002-06-18 Cepep Ab Cell penetrating peptides
ES2332590T3 (es) * 2003-01-15 2010-02-09 International Institute Of Cancer Immunology, Inc. Dimero peptidico.
US7976520B2 (en) * 2004-01-12 2011-07-12 Nulens Ltd. Eye wall anchored fixtures
US20110318380A1 (en) * 2008-10-01 2011-12-29 Dako Denmark A/S MHC Multimers in Cancer Vaccines and Immune Monitoring

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003524021A (ja) * 2000-02-22 2003-08-12 コリクサ コーポレイション 悪性中皮腫の診断および治療のための組成物および方法
WO2002028414A1 (en) 2000-10-06 2002-04-11 Corixa Corporation Compositions and methods for wt1 specific immunotherapy
JP2004510425A (ja) * 2000-10-06 2004-04-08 コリクサ　コーポレイション Ｗｔ１特異的免疫療法のための組成物および方法
JP2005518192A (ja) * 2001-10-30 2005-06-23 コリクサ コーポレイション Ｗｔ１特異的免疫療法のための組成物および方法
WO2003106682A1 (ja) 2002-06-12 2003-12-24 中外製薬株式会社 Ｈｌａ−ａ２４拘束性癌抗原ペプチド
WO2005095598A1 (ja) 2004-03-31 2005-10-13 International Institute Of Cancer Immunology, Inc. Ｗｔ１由来の癌抗原ペプチド
JP2006045287A (ja) 2004-08-02 2006-02-16 Inax Corp 弾性接着剤及びタイル張り壁面
JP2006280324A (ja) * 2005-04-04 2006-10-19 Ehime Univ Ｈｌａクラスｉｉ拘束性ｗｔ１抗原ペプチド

Non-Patent Citations (19)

* Cited by examiner, † Cited by third party
Title
"Peptide- Gosei No Kiso To Jikken", 1985, MARUZEN CO., LTD.
"Peptide Synthesis", 1966, INTERSCIENCE
"Peptide-Gosei", 1975, MARUZEN CO., LTD.
"Peptide-Gosei, Hirokawa", vol. 14, 1991, BOOK STORE, article "Iyakuhin No Kaihatsu (Zoku)"
"The Proteins", vol. 2, 1976, ACADEMIC PRESS INC.
CALL KM ET AL., CELL, vol. 60, no. 3, 9 February 1990 (1990-02-09), pages 509 - 20
DANIEL A. HABER ET AL., CELL, vol. 61, no. 7, 29 June 1990 (1990-06-29), pages 1257 - 69
GAO L ET AL., BLOOD, vol. 95, no. 7, 1 April 2000 (2000-04-01), pages 2198 - 203
INOUE K ET AL., BLOOD, vol. 91, no. 8, 15 April 1998 (1998-04-15), pages 2969 - 76
MELIEF CJ ET AL., IMMUNOL REV., vol. 145, June 1995 (1995-06-01), pages 167 - 77
MENKE AL ET AL., INT REV CYTOL., vol. 181, 1998, pages 151 - 212
OHMINAMI H ET AL., BLOOD, vol. 95, no. 1, 1 January 2000 (2000-01-01), pages 286 - 93
OKA Y ET AL., IMMUNOGENETICS, vol. 51, no. 2, February 2000 (2000-02-01), pages 99 - 107
OKA Y ET AL., J IMMUNOL., vol. 164, no. 4, 15 February 2000 (2000-02-15), pages 1873 - 80
RITZ J, J CLIN ONCOL., vol. 12, no. 2, February 1994 (1994-02-01), pages 237 - 8
See also references of EP2098595A4
TSUBOI A ET AL., J CLIN IMMUNOL., vol. 20, no. 3, May 2000 (2000-05-01), pages 195 - 202
TSUBOI A ET AL., LEUK RES., vol. 23, no. 5, May 1999 (1999-05-01), pages 499 - 505
YAMAGAMI T ET AL., BLOOD, vol. 87, no. 7, 1 April 1996 (1996-04-01), pages 2878 - 84

Cited By (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10124046B2 (en) 2003-11-05 2018-11-13 International Institute Of Cancer Immunology, Inc. HLA-DR-binding antigen peptide derived from WT1
US11027003B2 (en) 2003-11-05 2021-06-08 International Institute Of Cancer Immunology, Inc. HLA-DR-binding antigen peptide derived from WT1
US11555814B2 (en) 2007-02-27 2023-01-17 International Institute Of Cancer Immunology, Inc. Method for activation of helper t cell and composition for use in the method
US10139395B2 (en) 2007-02-27 2018-11-27 International Institute Of Cancer Immunology, Inc. Method for activation of helper T cell and composition for use in the method
US10654892B2 (en) 2010-10-05 2020-05-19 International Institute Of Cancer Immunology, Inc. Method for activating helper T cell
US12415833B2 (en) 2010-10-05 2025-09-16 International Institute Of Cancer Immunology, Inc. Method for activating helper T cell
US11091531B2 (en) 2012-09-12 2021-08-17 International Institute Of Cancer Immunology, Inc. Antigen-specific helper T-cell receptor genes
US10815288B2 (en) 2012-09-12 2020-10-27 International Institute Of Cancer Immunology, Inc. Antigen-specific helper T-cell receptor genes
US20160009781A1 (en) 2012-09-12 2016-01-14 International Institute Of Cancer Immunology, Inc. Antigen-specific helper t-cell receptor genes
US9833493B2 (en) 2012-12-17 2017-12-05 International Institute Of Cancer Immunology, Inc. Method for activating helper T cell
CN104995203B (zh) * 2012-12-17 2019-06-28 大塚制药株式会社 辅助性t细胞的活化方法
CN104995203A (zh) * 2012-12-17 2015-10-21 大塚制药株式会社 辅助性t细胞的活化方法
WO2014098012A1 (ja) * 2012-12-17 2014-06-26 大塚製薬株式会社 ヘルパーt細胞の活性化方法
EP2762152A1 (en) 2013-02-05 2014-08-06 Nitto Denko Corporation WT1 peptide cancer vaccine composition for transdermal administration
EP2762159A1 (en) 2013-02-05 2014-08-06 Nitto Denko Corporation WT1 peptide cancer vaccine composition for transdermal administration
EP2762160A1 (en) 2013-02-05 2014-08-06 Nitto Denko Corporation Wt1 peptide cancer vaccine composition for mucosal administration
EP2762156A1 (en) 2013-02-05 2014-08-06 Nitto Denko Corporation Tape preparation of WT1 peptide cancer vaccine for transdermal administration
EP3662927A2 (en) 2013-02-05 2020-06-10 Nitto Denko Corporation Vaccine composition
EP2762155A2 (en) 2013-02-05 2014-08-06 Nitto Denko Corporation Vaccine Composition
EP2762153A2 (en) 2013-02-05 2014-08-06 Nitto Denko Corporation Vaccine composition for mucosal administration
EP2762157A1 (en) 2013-02-05 2014-08-06 Nitto Denko Corporation Vaccine composition for transdermal or mucosal administration
EP2762154A2 (en) 2013-02-05 2014-08-06 Nitto Denko Corporation Vaccine composition for transdermal administration
US9181302B2 (en) 2013-03-29 2015-11-10 Sumitomo Dainippon Pharma Co., Ltd. WT1 antigen peptide conjugate vaccine
US9248173B2 (en) 2013-03-29 2016-02-02 Sumitomo Dainippon Pharma Co., Ltd. WT1 antigen peptide conjugate vaccine
JP2019069970A (ja) * 2013-03-29 2019-05-09 大日本住友製薬株式会社 Ｗｔ１抗原ペプチドコンジュゲートワクチン
JP2019089802A (ja) * 2013-03-29 2019-06-13 大日本住友製薬株式会社 Ｅｒａｐ１によるトリミング機能をきっかけとしたコンジュゲートワクチン
JPWO2014157692A1 (ja) * 2013-03-29 2017-02-16 大日本住友製薬株式会社 Ｗｔ１抗原ペプチドコンジュゲートワクチン
WO2014157692A1 (ja) * 2013-03-29 2014-10-02 大日本住友製薬株式会社 Ｗｔ１抗原ペプチドコンジュゲートワクチン
US11759509B2 (en) 2013-03-29 2023-09-19 Sumitomo Pharma Co., Ltd. WT1 antigen peptide conjugate vaccine
US10588952B2 (en) 2013-03-29 2020-03-17 Sumitomo Dainippon Pharma Co., Ltd. Conjugate vaccine using trimming function of ERAP1
WO2014157704A1 (ja) * 2013-03-29 2014-10-02 大日本住友製薬株式会社 Ｅｒａｐ１によるトリミング機能をきっかけとしたコンジュゲートワクチン
JPWO2014157704A1 (ja) * 2013-03-29 2017-02-16 大日本住友製薬株式会社 Ｅｒａｐ１によるトリミング機能をきっかけとしたコンジュゲートワクチン
JP2016155813A (ja) * 2013-03-29 2016-09-01 大日本住友製薬株式会社 Ｗｔ１抗原ペプチドコンジュゲートワクチン
KR102121638B1 (ko) 2013-03-29 2020-06-10 다이닛본 스미토모 세이야꾸 가부시끼가이샤 Wt1 항원 펩티드 콘쥬게이트 백신
KR20150135454A (ko) * 2013-03-29 2015-12-02 다이닛본 스미토모 세이야꾸 가부시끼가이샤 Wt1 항원 펩티드 콘쥬게이트 백신
AU2015362379B2 (en) * 2014-12-11 2020-05-14 International Institute Of Cancer Immunology, Inc. Immunotherapy for angiogenic disease
WO2016093326A1 (ja) * 2014-12-11 2016-06-16 株式会社癌免疫研究所 血管新生病の免疫療法
US11369656B2 (en) 2014-12-11 2022-06-28 International Institute Of Cancer Immunology, Inc. Immunotherapy for angiogenic disease
US11413322B2 (en) 2014-12-11 2022-08-16 International Institute Of Cancer Immunology, Inc. Immunotherapy for angiogenic disease
JPWO2016093326A1 (ja) * 2014-12-11 2017-09-14 株式会社癌免疫研究所 血管新生病の免疫療法
US10525096B2 (en) 2014-12-11 2020-01-07 International Institute Of Cancer Immunology, Inc. Immunotherapy for angiogenic disease
US12383608B2 (en) 2016-11-30 2025-08-12 Sumitomo Pharma Co., Ltd. WT1 helper peptides and combinations of WT1 helper peptide and conjugate of cancer antigen peptides
WO2019131722A1 (ja) * 2017-12-27 2019-07-04 大日本住友製薬株式会社 Ｗｔ１由来ペプチドのコンジュゲート体およびこれを含む組成物
JP7153287B2 (ja) 2020-05-12 2022-10-14 住友ファーマ株式会社 癌を処置するための医薬組成物
JP7209986B2 (ja) 2020-05-12 2023-01-23 住友ファーマ株式会社 癌を処置するための医薬組成物
JP2023036884A (ja) * 2020-05-12 2023-03-14 住友ファーマ株式会社 癌を処置するための医薬組成物
JP7248261B2 (ja) 2020-05-12 2023-03-29 住友ファーマ株式会社 癌を処置するための医薬組成物
JP2022180513A (ja) * 2020-05-12 2022-12-06 住友ファーマ株式会社 癌を処置するための医薬組成物
JPWO2021230247A1 (ja) * 2020-05-12 2021-11-18
WO2021230247A1 (ja) * 2020-05-12 2021-11-18 大日本住友製薬株式会社 癌を処置するための医薬組成物

Also Published As

Publication number Publication date
US20110098233A1 (en) 2011-04-28
EP2980219A1 (en) 2016-02-03
EP2341142B1 (en) 2014-11-26
CA2886622A1 (en) 2008-07-10
US9272026B2 (en) 2016-03-01
IL199052A0 (en) 2010-03-28
KR20090102772A (ko) 2009-09-30
EP3026115A1 (en) 2016-06-01
EP2479276A1 (en) 2012-07-25
AU2007340679B2 (en) 2013-09-12
EP2098595A4 (en) 2010-03-17
CN102659924B (zh) 2015-11-25
US8653038B2 (en) 2014-02-18
CA2886621A1 (en) 2008-07-10
IL215333A0 (en) 2011-11-30
SI2341142T1 (sl) 2015-03-31
US20160199472A1 (en) 2016-07-14
ZA200903633B (en) 2010-02-24
EP2341142A2 (en) 2011-07-06
NZ577443A (en) 2011-12-22
CN102302788A (zh) 2012-01-04
TWI417103B (zh) 2013-12-01
PT2341142E (pt) 2015-02-13
CN102335439B (zh) 2015-04-22
PH12014500902A1 (en) 2016-01-11
TWI554280B (zh) 2016-10-21
JP5484734B2 (ja) 2014-05-07
HK1159686A1 (en) 2012-08-03
HK1173187A1 (en) 2013-05-10
IL215332A0 (en) 2011-11-30
ES2629578T3 (es) 2017-08-11
CA2886619A1 (en) 2008-07-10
IL215334A0 (en) 2011-11-30
CN102335439A (zh) 2012-02-01
NZ592509A (en) 2012-11-30
EP2479275A1 (en) 2012-07-25
PL2341142T3 (pl) 2015-04-30
MY161664A (en) 2017-04-28
NZ592510A (en) 2012-11-30
TW200835513A (en) 2008-09-01
PH12014500902B1 (en) 2018-08-10
NZ601175A (en) 2012-12-21
EP2341142B8 (en) 2015-01-14
EP2479276B1 (en) 2015-12-09
AR064555A1 (es) 2009-04-08
CN102659924A (zh) 2012-09-12
UA103154C2 (uk) 2013-09-25
CA2670658A1 (en) 2008-07-10
KR101525261B1 (ko) 2015-06-02
ES2554775T3 (es) 2015-12-23
TW201345544A (zh) 2013-11-16
EP2479275B1 (en) 2015-10-28
HK1221252A1 (en) 2017-05-26
MX2009007008A (es) 2009-07-10
EP2980219B1 (en) 2018-11-14
US20140134200A1 (en) 2014-05-15
AU2007340679A1 (en) 2008-07-10
ES2556831T3 (es) 2016-01-20
DK2341142T3 (en) 2014-12-08
DK2479275T3 (en) 2015-12-14
EP3026115B1 (en) 2017-05-17
RU2009128979A (ru) 2011-02-10
EP2098595A1 (en) 2009-09-09
CA2886620A1 (en) 2008-07-10
EP2341142A3 (en) 2011-09-07
BRPI0720988A2 (pt) 2014-03-18
CY1116011T1 (el) 2017-01-25
DK2479276T3 (en) 2015-12-21
JPWO2008081701A1 (ja) 2010-04-30
CN102302788B (zh) 2016-06-15
CN102295682A (zh) 2011-12-28
US20180064795A1 (en) 2018-03-08
SG177222A1 (en) 2012-01-30
ES2526425T3 (es) 2015-01-12
NO20092774L (no) 2009-07-27
CN101573448A (zh) 2009-11-04
CN101573448B (zh) 2012-07-11
TWI599367B (zh) 2017-09-21
RU2481398C2 (ru) 2013-05-10
TW201630620A (zh) 2016-09-01

Similar Documents

Publication Publication Date Title
WO2008081701A1 (ja) Ｈｌａ－ａ＊１１０１拘束性ｗｔ１ペプチド、およびそれを含む医薬組成物
WO2005023866A3 (en) Peptides that inhibit complement activation
IL232501A (en) Peptide or polypeptide-resistant protein analogs and their uses
PH12012502372A1 (en) Hla-a*3303-restricted wt1 peptide and pharmaceutical composition comprising the same
WO2008118017A3 (en) Prame derived peptides and immunogenic compositions comprising these
WO2009004315A8 (en) Isolated peptides and uses thereof
NZ628987A (en) Extended recombinant polypeptides and compositions comprising same
WO2008043822A3 (en) Amino acid sequences that bind to a desired molecule in a conditional manner
WO2005116051A3 (de) An mhc-moleküle bindende tumor-assoziierte peptide
MXPA06001283A (es) Derivados de insulina novedosos.
BRPI0406800B8 (pt) "dímero de peptídeo, composição farmacêutica contendo o mesmo e seu uso
EP2508601A3 (en) Tem8 peptides and vaccines comprising the same
BRPI0718996B8 (pt) método para a preparação de um peptídio da fórmula h-d-?-nal-[cys-tyr-d-trp-lys-val-cys]-thr-nh2 ou h-d-?-nal-cys(acm)-tyr-d-trp-lys-val-cys(acm)-thr
WO2012109561A3 (en) Tripeptide compositions and methods for treatment of diabetes
WO2006087550A8 (en) Amyloid-binding peptides, analogues and uses thereof
WO2007145589A8 (en) Peptides that are capable of binding to amyloid-beta peptide.
WO2005059131A3 (en) Protein binding miniature proteins and uses thereof
MY147920A (en) Antibacterial and antiviral peptides from actinomadura namibiensis
WO2010011994A3 (en) Polypeptides and uses thereof
WO2009038729A3 (en) Compositions and methods utilizing fibrin beta chain fragments of the bbeta chain of fibrinogen
WO2010057275A8 (en) Cyclic peptides and uses thereof
EP1997826A3 (en) Synthetic ligands for immunoglobulins and pharmaceutical compositions containing them
WO2007000770A3 (en) Protein kinase c inhibitors for prevention of insulin resistance and type 2 diabetes
WO2006075253A3 (en) Peptides for desensitizing subjects allergic to dog hair and dander and compositions containing said peptides.
EP3771719A8 (en) A peptide binding to tau-protein

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780048749.1

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07850650

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2670658

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2007340679

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 577443

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2007850650

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2008552080

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 12009501279

Country of ref document: PH

ENP Entry into the national phase

Ref document number: 2007340679

Country of ref document: AU

Date of ref document: 20071214

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 12521533

Country of ref document: US

Ref document number: 3749/CHENP/2009

Country of ref document: IN

Ref document number: MX/A/2009/007008

Country of ref document: MX

Ref document number: 1020097013472

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2009061007

Country of ref document: EG

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2009128979

Country of ref document: RU

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: A200907944

Country of ref document: UA

Ref document number: 09078403

Country of ref document: CO

ENP Entry into the national phase

Ref document number: PI0720988

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20090629